Related Experiment Video

Updated: Jun 3, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Increasing burden of liver disease in patients with HIV infection

Deepak Joshi1, John O'Grady, Doug Dieterich

  • 1Institute of Liver Studies, King's College Hospital, London, UK.

Lancet (London, England)
|April 5, 2011
PubMed

Insights

Effective HIV treatment transforms HIV into a chronic condition, but increases liver disease risks from viral co-infections and non-alcoholic fatty liver disease. Management strategies are crucial for improving patient outcomes.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Immunology

Background:

  • Combined antiretroviral therapy (cART) has rendered human immunodeficiency virus (HIV) infection a chronic manageable condition.
  • While cART reduces AIDS-related mortality, liver disease burden has increased due to viral co-infections (hepatitis B and C), non-alcoholic fatty liver disease (NAFLD), drug-induced liver injury (DILI), and hepatocellular carcinoma (HCC).

Purpose of the Study:

  • To provide a comprehensive overview of the primary causes and pathogenesis of liver disease in individuals with HIV infection.
  • To discuss current and emerging treatment strategies for liver disease in the context of HIV management, including the role of liver transplantation.

Main Methods:

  • Literature review and synthesis of existing research on HIV and liver disease.
  • Analysis of epidemiological data and clinical studies concerning liver co-morbidities in HIV-infected individuals.

Main Results:

  • HIV co-infection with hepatitis B and C viruses significantly contributes to liver morbidity and mortality.
  • Non-alcoholic fatty liver disease and drug-induced hepatotoxicity are increasingly recognized as major contributors to liver disease in the HIV-positive population.
  • Hepatocellular carcinoma development is a significant concern, necessitating proactive screening and management.

Conclusions:

  • Integrated management strategies addressing viral hepatitis, NAFLD, DILI, and HCC are essential for mitigating liver disease in HIV-infected patients.
  • The role of liver transplantation is evolving and may offer a viable option for select patients with end-stage liver disease due to HIV-related complications.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment07:21

Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment

Published on: June 23, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...